Form 8-K - Current report:
SEC Accession No. 0000950170-24-126346
Filing Date
2024-11-13
Accepted
2024-11-13 16:17:25
Documents
13
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fdmt-20241113.htm   iXBRL 8-K 41161
2 EX-99.1 fdmt-ex99_1.htm EX-99.1 138585
3 GRAPHIC img216297824_0.jpg GRAPHIC 6182
  Complete submission text file 0000950170-24-126346.txt   318744

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fdmt-20241113.xsd EX-101.SCH 25898
15 EXTRACTED XBRL INSTANCE DOCUMENT fdmt-20241113_htm.xml XML 4890
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 241454530
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)